1. PBMs are increasingly using “clawbacks,” which is extra money paid to PBMs by insured patients meeting their copays rather than paying the cheaper list price. The so-called clawbacks have prompted at least 16 lawsuits in six months. (Bloomberg)

2. Merck’s experimental antiviral drug letermovir prevented serious infection after bone marrow transplant. The drugmaker expects to submit its application to the FDA later this year. (Reuters)

3. The European Medicine Agency recommended the combined use of Novartis’ Tafinlar and Mekinist for adults with advanced non-small cell lung cancer. The combination cancer therapy competes with Roche’s Cotellic and Zelboraf. (Reuters)

4. Forty-three percent of people taking anti-addiction medication buprenorphine are also prescribed at least one opioid, a study found. This study’s findings highlight some of the challenges to addiction treatment. (WaPo)

5. ICYMI: Drugmakers such as Gilead Sciences, Bristol-Myers Squibb, and AbbVie are paying professors and economists from leading universities to combat President Trump’s criticism of drug prices. Not all of the professors and economists have disclosed their ties to the industry. (ProPublica)